Sex-Discordant Fecal Microbiota Transplantation for Clostridioides difficile May Increase Risk of Postinfection Irritable Bowel Syndrome
Fecal microbiota transplantation (FMT) is the cornerstone for the management of recurrent Clostridioides difficile infection (rCDI) with high clinical success rates with restoration of the microbiome.1,2 FMT is considered safe and effective on short-term and long-term follow-up.3,4 However, adverse events such as weight gain, diarrhea, abdominal cramping, bloating, nausea, constipation, and pathogen transmission after FMT have been commonly reported with no defined risk factors for these adverse events.
